{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:43:39Z","timestamp":1792590219261,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T00:00:00Z","timestamp":1680393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/15\/103\/31900"],"award-info":[{"award-number":["PG\/15\/103\/31900"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtha.2023.02.011","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T13:07:22Z","timestamp":1676898442000},"page":"1544-1552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"21","author":[{"given":"Mary I.","family":"Underwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferras","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie A.","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.B.","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.02.011_bib1","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2011-02-306597","article-title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor","volume":"118","author":"Crawley","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib2","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in\u00a0vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib3","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V89.9.3097","article-title":"Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura","volume":"89","author":"Furlan","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.02.011_bib5","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib6","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood.V91.8.2839.2839_2839_2846","article-title":"Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura","volume":"91","author":"Furlan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.02.011_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.12718","article-title":"How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome","volume":"164","author":"Scully","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.02.011_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.02.011_bib10","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtha.2023.02.011_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.019299","article-title":"Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura","volume":"95","author":"Zheng","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.02.011_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1160\/TH04-05-0301","article-title":"The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura","volume":"93","author":"Luken","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib15","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib16","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1538-7836.2006.02025.x","article-title":"Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in\u00a0vivo","volume":"4","author":"Shelat","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1160\/TH05-08-0550","article-title":"Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)","volume":"95","author":"Rieger","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2006.01833.x","article-title":"ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences","volume":"4","author":"Feys","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1538-7836.2011.04548.x","article-title":"Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura","volume":"10","author":"Ferrari","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib21","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.02.011_bib23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1160\/TH06-02-0100","article-title":"ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura","volume":"95","author":"Tsai","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib26","first-page":"7","article-title":"Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines","author":"Winters","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program 2012"},{"key":"10.1016\/j.jtha.2023.02.011_bib27","doi-asserted-by":"crossref","first-page":"18584","DOI":"10.1073\/pnas.1413282112","article-title":"Allosteric activation of ADAMTS13 by von Willebrand factor","volume":"111","author":"Muia","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.02.011_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jth.14345","article-title":"Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura","volume":"17","author":"Taylor","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.02.011_bib30","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2012.04808.x","article-title":"ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura","volume":"10","author":"Bettoni","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib31","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3389\/fimmu.2018.01646","article-title":"Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura","volume":"9","author":"Sinkovits","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.02.011_bib33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Ferrari","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.011_bib34","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.011_bib35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1084\/jem.166.5.1351","article-title":"Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies","volume":"166","author":"Br\u00fcggemann","year":"1987","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jtha.2023.02.011_bib36","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.137.11.3566","article-title":"Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency","volume":"137","author":"van der Zee","year":"1986","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtha.2023.02.011_bib37","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:46Z","timestamp":1761536326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1538783623001599"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.02.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742542783.793599091","asserted-by":"object"}]},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}